Berkeley, CA, United States
Berkeley, CA, United States

Time filter

Source Type

On Thursday, shares in New York-based Progenics Pharmaceuticals Inc. rose 1.25%, ending the day at $7.30. The stock recorded a trading volume of 785,663 shares. The Company's shares are trading below their 200-day moving average by 8.85%. Moreover, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have a Relative Strength Index (RSI) of 37.98. On May 04th, 2017, Progenics Pharma announced financial results for Q1 2017. Revenue for Q1 2017 totaled $2.3 million, down from $2.5 million in Q1 2016. Net loss attributable to the Company for the quarter was $16.4 million, compared to a net loss of $12.7 million in the corresponding 2016 period. Additionally, R&D expenses increased by $0.9 million, and general and administrative expenses decreased by $0.1 million during the quarter. PGNX complete research report is just a click away and free at: Shares in Berkeley, California headquartered Dynavax Technologies Corp. ended the day 0.89% lower at $5.55 with a total trading volume of 607,211 shares. In the last month and the previous three months, the stock has gained 6.73% and 38.75%, respectively. Additionally, the Company's shares have advanced 40.51% on an YTD basis. The stock is trading below its 50-day moving average by 3.23%. Furthermore, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have an RSI of 49.19. On May 08th, 2017, Dynavax Technologies reported financial results for Q1 2017. Cash, cash equivalents, and marketable securities were $85.4 million at March 31st, 2017; net loss was $25.3 million, or $0.60 per share; R&D expenses were $16.3 million; and general and administrative expenses were $6.5 million. On May 09th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $6 a share to $7 a share. The complimentary report on DVAX can be downloaded at: http://stock-callers.com/registration/?symbol=DVAX At the close of trading on Thursday, shares in Germantown, Maryland-based Intrexon Corp. finished 20.76% higher at $23.62. A total volume of 5.32 million shares was traded, which was above their three months average volume of 1.07 million shares. The stock has advanced 20.02% in the last one month and 9.10% over the previous three months. The Company's shares are trading above their 50-day moving average by 14.65%. Additionally, shares of Intrexon, which operates in the synthetic biology field in the US, have an RSI of 69.39. On May 10th, 2017, Intrexon and Darling Ingredients Inc. announced that their joint venture, EnviroFlight, LLC, plans to significantly expand production of advanced ingredients for sustainable feed and nutrition derived from black soldier fly (BSF) larvae through the largest, commercial-scale BSF larvae production facility in the US. Initial production capacity is expected in Q1 2018, and will be targeted toward supplying livestock, aquaculture, and pet food markets. Sign up for your complimentary research report on XON at: Durham, North Carolina-based Heat Biologics Inc.'s shares recorded a trading volume of 153,023 shares at the end of yesterday's session. The stock closed the day 3.55% higher at $0.73. The Company's shares are trading below their 50-day moving average by 12.21%. Additionally, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the US, have an RSI of 38.38. On May 01st, 2017, Heat Biologics announced that the Company has completed the acquisition of an 80% controlling interest in Pelican Therapeutics, Inc., a privately held immuno-oncology company focused on developing agonists to TNFRSF25, a differentiated and potentially best-in-class T cell costimulatory receptor. Heat also announced its appointment of industry veteran and Pelican board member Rahul Jasuja, Ph.D. as the new CEO of the Pelican subsidiary. Get free access to your research report on HTBX at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system. Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=966744 . (This report is available at upto 25% Discount till June 02nd 2017.) "Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


News Article | April 18, 2017
Site: marketersmedia.com

Wiseguyreports.Com Adds “ALL Vaccine -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies the ALL Vaccine market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the ALL Vaccine market by product type and applications/end industries. The global ALL Vaccine market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of ALL Vaccine. Europe also play important roles in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of XX. Pfizer, Inc., Glaxosmithkline, PLC., Merck & Co., Inc., Novarits, Sanofi Pasteur, CSL Limited, Emergent Biosolutions, Inc., Johnson & Johnson, Medimmune, LLC. (A Subsidiary of Astrazeneca), Astellas Pharma Inc., Mitsubishi Tanabe, Dynavax Technologies, Novavax Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of ALL Vaccine in these regions, from 2012 to 2022 (forecast), covering On the basis of product, the ALL Vaccine market is primarily split into Vaccinia Measles, mumps, rubella Varicella Influenza Rotavirus Zoster Yellow Fever Polio Hepatitis A Rabies BCG Diphtheria, tetanus Hepatitis B Haemophilus influenzae type b Pertussis Human papillomavirus Meningococcal Pneumococcal On the basis on the end users/applications, this report covers For Adult For Child Global ALL Vaccine Sales Market Report 2017 1 ALL Vaccine Market Overview 1.1 Product Overview and Scope of ALL Vaccine 1.2 Classification of ALL Vaccine by Product Category 1.2.1 Global ALL Vaccine Sales (K Units) and Growth (%) Comparison by Types (2012-2022) 1.2.2 Global ALL Vaccine Sales Market Share (%) by Types in 2016 1.2.3 Vaccinia 1.2.4 Measles, mumps, rubella 1.2.5 Varicella 1.2.5 Influenza 1.2.5 Rotavirus 1.2.6 Zoster 1.2.7 Yellow Fever 1.2.8 Polio 1.2.9 Hepatitis A 1.2.10 Rabies 1.2.11 BCG 1.2.12 Diphtheria, tetanus 1.2.13 Hepatitis B 1.2.14 Haemophilus influenzae type b 1.2.15 Pertussis 1.2.16 Human papillomavirus 1.2.17 Meningococcal 1.2.18 Pneumococcal 9 Global ALL Vaccine Players Profiles and Sales Data 9.1 Pfizer, Inc. 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 ALL Vaccine Product Category, Application and Specification 9.1.2.1 Product A 9.1.2.2 Product B 9.1.3 Pfizer, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Glaxosmithkline, PLC. 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 ALL Vaccine Product Category, Application and Specification 9.2.2.1 Product A 9.2.2.2 Product B 9.2.3 Glaxosmithkline, PLC. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Merck & Co., Inc. 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 ALL Vaccine Product Category, Application and Specification 9.3.2.1 Product A 9.3.2.2 Product B 9.3.3 Merck & Co., Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.3.4 Main Business/Business Overview 9.4 Novarits 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 ALL Vaccine Product Category, Application and Specification 9.4.2.1 Product A 9.4.2.2 Product B 9.4.3 Novarits ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.4.4 Main Business/Business Overview 9.5 Sanofi Pasteur 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 ALL Vaccine Product Category, Application and Specification 9.5.2.1 Product A 9.5.2.2 Product B 9.5.3 Sanofi Pasteur ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.5.4 Main Business/Business Overview 9.6 CSL Limited 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 ALL Vaccine Product Category, Application and Specification 9.6.2.1 Product A 9.6.2.2 Product B 9.6.3 CSL Limited ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.6.4 Main Business/Business Overview 9.7 Emergent Biosolutions, Inc. 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 ALL Vaccine Product Category, Application and Specification 9.7.2.1 Product A 9.7.2.2 Product B 9.7.3 Emergent Biosolutions, Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.7.4 Main Business/Business Overview 9.8 Johnson & Johnson 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 ALL Vaccine Product Category, Application and Specification 9.8.2.1 Product A 9.8.2.2 Product B 9.8.3 Johnson & Johnson ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.8.4 Main Business/Business Overview 9.9 Medimmune, LLC. (A Subsidiary of Astrazeneca) 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 ALL Vaccine Product Category, Application and Specification 9.9.2.1 Product A 9.9.2.2 Product B 9.9.3 Medimmune, LLC. (A Subsidiary of Astrazeneca) ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.9.4 Main Business/Business Overview 9.10 Astellas Pharma Inc. 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 ALL Vaccine Product Category, Application and Specification 9.10.2.1 Product A 9.10.2.2 Product B 9.10.3 Astellas Pharma Inc. ALL Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017) 9.10.4 Main Business/Business Overview 9.11 Mitsubishi Tanabe 9.12 Dynavax Technologies 9.13 Novavax For more information, please visit https://www.wiseguyreports.com/sample-request/1193278-global-all-vaccine-sales-market-report-2017

Loading Dynavax Technologies collaborators
Loading Dynavax Technologies collaborators